Health

STAT+: A patient died in a Bristol Myers Squibb autoimmune CAR-T trial.

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 23/10/2026, 21:06:24 UTC.

Briefings

Bristol Myers Squibb reported a fatal case in a Phase 1 autoimmune CAR-T trial for multiple sclerosis, where a patient died from septic pneumonia after failing to respond to standard treatments. The company stated the patient had other unresolved complications complicating the root cause analysis. This event highlights safety concerns in early-stage autoimmune therapy research.

Key points

• A patient died from septic pneumonia after failing to respond to standard autoimmune treatments in a Phase 1 trial for multiple sclerosis.
• Bristol Myers Squibb stated the patient had other unresolved complications complicating the determination of the root cause of the death.

Context

This fatal case occurred in an early Phase 1 trial testing a CAR-T therapy for multiple sclerosis, a condition causing muscle weakness and fatigue. The death adds to safety concerns in the growing field of autoimmune research, prompting continued monitoring of trial outcomes.

Limitations

The evidence is limited to a single reported case from a press release. The company explicitly stated that prior complications confounded the ability to determine the root cause of the issue. No specific dates for the patient's death or trial duration are provided in the source.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 23/10/2026, 21:08:07 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeieyjparin6myq4cquaqvierp26cazodxsbfavkchtridmzgzvwnke